Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Karydas Daphne reported acquisition or exercise transactions in this Form 4 filing.
Mineralys Therapeutics, Inc. director Daphne Karydas reported equity awards consisting of stock options and restricted stock units. She was granted stock options for 8,300 shares at a price of $0.00 per share, vesting in 12 substantially equal monthly installments following the grant date.
She also received 6,200 restricted stock units (RSUs)
Mineralys Therapeutics, Inc. director and more than 10% owner Brian Taylor Slingsby reported equity awards and related transfers on February 19, 2026. He received 8,300 stock options and 6,200 restricted stock units (RSUs) at an exercise/award price of $0.00 per share.
The RSUs give a contingent right to one common share each and vest in one annual installment after the grant date, while the stock options vest in 12 substantially equal monthly installments following the grant date. Certain options and RSUs were transferred under an option transfer agreement to Catalys Pacific Fund, LP, and some securities are held of record by that fund.
Catalys Pacific Fund, LP’s general partner is Catalys Pacific Fund GP, LP, whose general partner is Catalys Pacific, LLC. These entities and Brian Taylor Slingsby may be deemed to share voting and investment power over shares held by the fund, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
Mineralys Therapeutics director and 10% owner Srinivas Akkaraju reported equity grants. On February 19, 2026, he acquired a stock option covering 8,300 shares at $0.00 per share and 6,200 shares of common stock granted for no cash consideration as restricted stock units.
The footnotes state each RSU represents one share of common stock that vests in one annual installment following the grant date, while the stock option vests in 12 substantially equal monthly installments after grant. The filing also reports indirect ownership of 5,871,018 common shares held through Samsara Opportunity Fund, L.P. and Samsara BioCapital L.P., over which Dr. Akkaraju has voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.
DiRocco Derek reported acquisition or exercise transactions in this Form 4 filing.
Mineralys Therapeutics, Inc. director Derek DiRocco reported awards linked to company equity that he holds for the benefit of RA Capital-managed funds. He was granted stock options for 8,300 shares and restricted stock units representing 6,200 shares of common stock, each at a price of $0.0000 per share.
According to the disclosure, these stock options vest in 12 substantially equal monthly installments after the grant date, while the restricted stock units vest in one annual installment after the grant date. Under an arrangement with RA Capital Management, L.P., any net cash or stock from these awards is turned over to RA Capital Healthcare Fund, L.P. and RA Capital Nexus III Fund, L.P., and DiRocco disclaims beneficial ownership of the awards and underlying common stock.
Mineralys Therapeutics reported that Chief Medical Officer David Malcom acquired new equity awards on February 19, 2026. He received 51,300 stock options with an exercise price of $0.00 per share and now holds 51,300 options in total. He also received 38,400 shares of common stock for no cash consideration, increasing his direct common share holdings to 82,489 shares. The 38,400-share grant is in the form of restricted stock units that vest in four equal annual installments on each one-year anniversary of the grant date. The stock options vest separately in 48 equal monthly installments over four years following the grant date.
Levy Adam Scott reported acquisition or exercise transactions in this Form 4 filing.
Mineralys Therapeutics CFO Adam Scott Levy reported equity awards consisting of stock options and restricted stock units. He was granted 53,300 stock options and RSUs covering 39,900 shares of common stock, each at a reported price of $0.00 per share as compensation rather than open-market purchases.
The RSUs were granted for no additional cash consideration and represent contingent rights to receive common stock upon vesting. They vest in four equal annual installments on each one-year anniversary of the grant date. The stock options vest separately in 48 equal monthly installments over four years, with 1/48th of the option vesting each month after the grant date.
Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option and stock transactions in company shares. On February 17, 2026, he exercised a stock option for 417 shares of common stock at $15.44 per share and then sold 417 shares at $27.59 per share.
After these transactions, he directly owned 44,089 shares of common stock and 5,417 stock options. The filing states the trades were carried out under a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were pre-arranged rather than discretionary trades.
Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers 417 shares of Mineralys Therapeutics, Inc. common stock to be sold through Merrill Lynch on or about February 17, 2026 on the NASDAQ market, with an aggregate market value of $11,505.03.
The 417 shares were acquired the same day through the exercise of employee stock options via a broker-assisted cashless exercise. The notice also lists prior sales of Mineralys common stock by David Rodman over the past three months, including 192,715 shares sold on January 5, 2026 for gross proceeds of $6,749,100.06 and 70,037 shares sold on January 2, 2026 for $2,511,919.03.
Mineralys Therapeutics (MLYS) Chief Medical Officer Rodman David Malcom reported option exercises and share sales in mid-February 2026. On February 12 and 13, 2026, he exercised stock options for 6,349, 3,541 and 4,166 common shares at exercise prices of $1.08, $10.20 and $14.25 per share.
He then sold portions of the resulting common stock in open‑market transactions at weighted‑average prices of $28.9353, $29.6387, $27.33 and $27.5835, all under a Rule 10b5‑1 trading plan adopted on October 6, 2025. After these transactions, he directly owned 44,089 shares of common stock, along with multiple remaining stock option positions.
Mineralys Therapeutics, Inc. received an amended Schedule 13G showing that investment entities affiliated with Catalys Pacific and individual reporting person Brian Taylor Slingsby collectively report beneficial ownership of 8,002,738 shares of common stock, or 10.1% of the class as of December 31, 2025.
The filing states that 7,903,838 shares are held of record by Catalys Pacific Fund, LP, with an additional 98,900 shares underlying stock options exercisable within 60 days of December 31, 2025. All reporting persons report shared voting and dispositive power over these 8,002,738 shares, and no sole voting or dispositive power.